Click here for slides on this topic


Vildagliptin

An oral antihyperglycemic agent of the dipeptidyl peptidase-4 (DPP-4) inhibitor class.
The following content matched the glossary term: Vildagliptin

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 9, 2012

Top

Daily coverage of American Diabetes Association 72nd Scientific Sessions  June 9, 2012

Results from the EASIE, EUREXA, TODAY, and Diabetes Prevention Program (DPP) trials; new data on SGLT2 inhibitors for diabetes treatment, incretins for diabetes treatment, ATP-IV guideline update, and more.

 

ADA/European Association for the Study of Diabetes (EASD) Position Statement on Hyperglycemia Management in Type 2 Diabetes

Top

Joint position statement from ADA/EASD with clinical practice recommendations for managing hyperglycemia in type 2 diabetes

Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment

Top

Banerji MA, Purkayastha D, Francis BH. Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: A retrospective analysis of the GALIANT study. Diabetes Res Clin Pract. 2010 July 22. [Epub ahead of print]. This retrospective analysis assessed safety and tolerability of vildagliptin (Vilda) as an add-on to metformin in type 2 diabetes mellitus (T2DM) patients with normal renal function (GFR >80mL/min/1.73m(2)) and mild renal impairment (GFR: >50 to =80mL/min/1.73m(2)). 

Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial

Top

Schweizer A, Dejager S, Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes, Obesity and Metabolism. 2009;11(8):804-812. This study evaluated the efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor, vildagliptin, and metformin in drug-naive elderly patients with type 2 diabetes.

Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus

Top

Rosenstock J, Niggli M, Maldonado-Lutomirsky M. Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism. 2009 Mar 28. [Epub ahead of print]. To assess the long-term safety and the sustained glycaemic control of vildagliptin compared with rosiglitazone over 2-year treatment in drug-naïve type 2 diabetes mellitus patients.

Vildagliptin + metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients w/ type 2 diabetes mellitus

Top

Bosi E, Dotta F, Jia Y, Goodman M. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism. 2009;11(5):506-515. To compare the efficacy and safety of vildagliptin and metformin initial combination therapy with individual monotherapies in treatment-naive patients with type 2 diabetes mellitus (T2DM).

Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus

Top

Tahrani AA, Piya MK, Barnett AH. Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Adv Ther. 2009;26(3):249-262. Type 2 diabetes mellitus (T2DM) is a global epidemic with increasing impact on individuals and healthcare providers. Available treatments (such as metformin, sulfonylureas, glitazones, and insulin) have proven unsatisfactory in producing a long-lasting impact on glycemic control.

Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes

Top

D'Alessio DA, Denney AM, Hermiller LM, et al. Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.J Clin Endocrinol Metab. 2009;94(1):81-88. Dipeptidyl peptidase 4 (DPP-4) inhibitors are proposed to lower blood glucose in type 2 diabetes mellitus (T2DM) by prolonging the activity of the circulating incretins, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1).

Overview of the gliptin class (dipeptidyl peptidase-4 inhibitors) in clinical practice

Top

Bohannon N. Overview of the gliptin class (dipeptidyl peptidase-4 inhibitors) in clinical practice. Postgrad Med. 2009;121(1):40-45. Dipeptidyl peptidase-4 inhibitors (DPP-4s), also commonly called gliptins, are a relatively new class of drugs for the treatment of type 2 diabetes.

Impact of incretin therapy on islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes

Top

McGill JB. Impact of incretin therapy on islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes. Postgrad Med. 2009;121(1):46-58. Glucose homeostasis is governed by a complex interplay of hormonal signaling and modulation. Insulin, glucagon, amylin, the incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), and other hormones and enzymes interact to maintain glucose homeostasis and normal cellular metabolism. 

1 2 3 4 Next 

Slide Library Results

Search Results for: Vildagliptin Slides Found: 19
Vildagliptin Monotherapy Improves Glycemic Control in Type 2 Diabetes
Sustained Reduction in A1C During 1-Yr Treatment With Vildagliptin in Patients With T2D
Vildagliptin Is as Effective as Rosiglitazone in Lowering A1C but Without Weight Gain in Drug-Naïve Patients With T2D
Vildagliptin + Pioglitazone Improves A1C in Patients Not Controlled With Thiazolidinedione Monotherapy
Vildagliptin + Pioglitazone Increases Beta-Cell Insulin Secretory Rate
Vildagliptin: Change in Mean A1C During 24-Week Treatment
Vildagliptin: Percentage of Patients Achieving A1C <7%
Vildagliptin vs Rosiglitazone Monotherapy in Type 2 Diabetes: Effects on Body Weight
Vildagliptin vs Rosiglitazone Monotherapy in Type 2 Diabetes: Effects on Lipids
Frequent Adverse Events in Diabetic Patients Treated With GLP-1 Analogues
Frequent Adverse Events in Diabetic Patients Treated With DPP-4 Inhibitors
Change in A1C for DPP-4 Inhibitors vs Control in Diabetic Adults
Change in A1C for DPP-4 Inhibitors vs Control in Diabetic Adults (cont)
Effect of Vildagliptin Added to Glimepiride on ß-Cell Function in Patients With Type 2 Diabetes
Fasting Levels of Intact GIP and GLP-1 Concentrations and DPP-4 Activity in Patients With Diabetes
Vildagliptin vs Metformin: A1C
Incretin Therapies Vs Sulfonylureas Pancreatitis Type 2 Diabetes | NDEI
Risk of Acute Pancreatitis Rare in Incretin-Treated Type 2 Diabetes | NDEI
No Increased Acute Pancreatitis Risk With Incretins Type 2 Diabetes | NDEI